Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa.

•The RTS,S/AS01 malaria vaccine was assessed in a phase 3 trial in sub-Saharan Africa.•We evaluated the vaccine in a subset of children identified as HIV+ in this trial.•The safety of RTS,S/AS01 in HIV+ children was similar to that of comparator vaccines.•RTS,S/AS01 was immunogenic in HIV+ children.•Antibody levels in HIV+ children were lower than in children with unknown HIV status.